Mint Podcast Podcast Por Mint - HT Smartcast arte de portada

Mint Podcast

Mint Podcast

De: Mint - HT Smartcast
Escúchala gratis

Acerca de esta escucha

Welcome to Mint Podcast, your ultimate destination for insightful discussions on business, finance, and the economy. Stay ahead with the latest business news, financial insights, and expert opinions that shape markets and industries. Our podcast features in-depth analysis, exclusive interviews with top policy makers and business leaders, and compelling stories spanning across personal finance, technology, and economic trends. Under the Mint Podcast umbrella, we bring you a few powerhouse series: Top Of The Morning Founder Diaries Rollin’ with the Boss Mint Money TalksMint - HT Smartcast Economía
Episodios
  • Mint Podcast: Just Split Your Portfolio Equally Across These Asset Classes, It's Better Than...: Swanand Kelkar |
    May 14 2025

    In this episode of Where To Invest Rs 10 Lakhs today, we speak to the Managing Partner at Breakout Capital Advisors, Swanand Kelkar. Unlike most other fund managers, his story is different, as are his ideas. Kelkar tells us where he would invest his money today, why investing equally across 4 asset classes gives better return than investing in the asset class which got the best returns in the previous year, and why he thinks just sticking to you asset allocation plan is the best way to go about things. Watch the full episode on YouTube- https://www.youtube.com/watch?v=YpVoWMHLkws#money #stockmarket #finance

    Más Menos
    41 m
  • Mint Podcast: If You're Taking A Home Loan, Ensure Your Bank Does Not Trick You Into Buying This Insurance
    May 14 2025

    One of the most common forms of insurance mis-selling is something called liability insurance. When you take a home loan from a bank, the RM usually tells you that it's compulsory for you to take this kind of life insurance, which is called liability insurance because it is tied to your home loan.BUT - that is not really the case. Here's how you should deal with it.

    Watch the full episode on YouTube- https://www.youtube.com/watch?v=gDrRUq2mQEc#money #personalfinance #finance

    Más Menos
    4 m
  • Top of the Morning : Airtel, Tata & Hero - Earnings Overview | IND-US, Tariff Tensions Simmer Again
    May 14 2025

    India vs. US:

    Trade Tensions Heat UpIndia is ready to hit back with $1.91 billion in tariffs on key US goods—like almonds, petrochemicals, and medical devices—if steel and aluminium duties aren’t withdrawn by June 8. The trigger? Trump’s extension of safeguard duties. Commerce Minister Piyush Goyal heads to Washington on May 16 to try and broker a deal. With $7.6B in exports on the line and a 90-day tariff pause set to expire on July 8, India’s playing hardball while still betting on a Free Trade Agreement.


    Airtel’s Q4 Rings Loud

    Bharti Airtel posted a stunning 432% jump in Q4FY25 net profit at ₹11,022 crore, riding high on tariff hikes and a one-time tax gain. Revenue rose 27% to ₹47,876 crore, while ARPU hit ₹245. With 590.5 million users, the company also sealed a satellite internet pact with Elon Musk’s Starlink. A ₹16/share final dividend caps off a blockbuster year.


    Tata’s Mixed Drive

    Tata Motors saw Q4 profit drop 51% YoY to ₹8,470 crore, but FY25 revenue hit a record ₹4.39 lakh crore. JLR’s PBT soared to a decade-high £2.5 billion, and Tata’s EV arm turned EBITDA positive. Challenges persist in passenger vehicles, but the company remains debt-free and optimistic. A ₹6 dividend and a key Investor Day on June 16 are on the radar.


    Hero’s Global EV Push

    Hero MotoCorp’s FY25 net profit rose 16% to ₹4,610 crore. Exports jumped 44%, and EV sales rocketed 175%, with its Vida brand doubling market share. But rivals like Honda and TVS are growing faster. Hero plans European expansion and is betting big on EVs and new three-wheeler plays via Euler Motors.


    Cipla Steady Amid Policy Storm

    Cipla shrugged off US pharma tariff fears and posted a 30% jump in Q4 profit to ₹1,222 crore. FY25 revenue grew 8% to ₹27,548 crore. The US remains key, now forming 29% of revenue, while India remains the long-term play. With GLP-1 drugs like Ozempic going off patent soon, Cipla’s gearing up with in-house and partner products for the next leg of growth.

    Más Menos
    8 m
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones